Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2008 1
2009 4
2012 2
2013 4
2014 1
2015 3
2016 1
2017 4
2018 7
2019 8
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Results by year
Filters applied: . Clear all
Page 1
Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies.
Nikolic K, Mavridis L, Djikic T, Vucicevic J, Agbaba D, Yelekci K, Mitchell JB. Nikolic K, et al. Among authors: yelekci k. Front Neurosci. 2016 Jun 10;10:265. doi: 10.3389/fnins.2016.00265. eCollection 2016. Front Neurosci. 2016. PMID: 27375423 Free PMC article. Review.
Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitors.
Coşkun GP, Djikic T, Hayal TB, Türkel N, Yelekçi K, Şahin F, Küçükgüzel ŞG. Coşkun GP, et al. Among authors: yelekci k. Molecules. 2018 Aug 6;23(8):1969. doi: 10.3390/molecules23081969. Molecules. 2018. PMID: 30082676 Free PMC article.
Synthesis, anticancer activity, and molecular modeling of etodolac-thioether derivatives as potent methionine aminopeptidase (type II) inhibitors.
Çoruh I, Çevik Ö, Yelekçi K, Djikic T, Küçükgüzel ŞG. Çoruh I, et al. Among authors: yelekci k. Arch Pharm (Weinheim). 2018 Apr;351(3-4):e1700195. doi: 10.1002/ardp.201700195. Epub 2018 Mar 25. Arch Pharm (Weinheim). 2018. PMID: 29575045
Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors.
Ibrahim Uba A, Yelekçi K. Ibrahim Uba A, et al. Among authors: yelekci k. J Biomol Struct Dyn. 2019 Sep;37(14):3627-3636. doi: 10.1080/07391102.2018.1521747. Epub 2019 Jan 10. J Biomol Struct Dyn. 2019. PMID: 30204052
Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI, Yelekçi K. Uba AI, et al. Among authors: yelekci k. J Biomol Struct Dyn. 2018 Sep;36(12):3231-3245. doi: 10.1080/07391102.2017.1384402. Epub 2017 Oct 23. J Biomol Struct Dyn. 2018. PMID: 28938863
Absolute configuration and biological profile of pyrazoline enantiomers as MAO inhibitory activity.
Goksen US, Sarigul S, Bultinck P, Herrebout W, Dogan I, Yelekci K, Ucar G, Gokhan Kelekci N. Goksen US, et al. Among authors: yelekci k. Chirality. 2019 Jan;31(1):21-33. doi: 10.1002/chir.23027. Epub 2018 Nov 23. Chirality. 2019. PMID: 30468523
Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
Uba AI, Yelekçi K. Uba AI, et al. Among authors: yelekci k. Comput Biol Chem. 2018 Aug;75:131-142. doi: 10.1016/j.compbiolchem.2018.05.004. Epub 2018 May 16. Comput Biol Chem. 2018. PMID: 29859380
Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes.
Elmezayen AD, Al-Obaidi A, Şahin AT, Yelekçi K. Elmezayen AD, et al. Among authors: yelekci k. J Biomol Struct Dyn. 2020 Apr 26:1-13. doi: 10.1080/07391102.2020.1758791. Online ahead of print. J Biomol Struct Dyn. 2020. PMID: 32306862 Free PMC article.
Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities.
Djikic T, Martí Y, Spyrakis F, Lau T, Benedetti P, Davey G, Schloss P, Yelekci K. Djikic T, et al. Among authors: yelekci k. J Biomol Struct Dyn. 2019 Feb;37(2):291-306. doi: 10.1080/07391102.2018.1426044. Epub 2018 Jan 26. J Biomol Struct Dyn. 2019. PMID: 29334320 Free article.
35 results
Jump to page